---
title: 'Vice President, Clinical Development at Remix Therapeutics'
canonical: 'https://feeny.ai/job/vice-president-clinical-development-remix-therapeutics-watertown-0ewyfa0bvx9g'
type: 'job'
last_seen: '2026-10-24'
---

# Vice President, Clinical Development at Remix Therapeutics

- **Company:** Remix Therapeutics
- **Location:** Watertown, MA
- **Posted:** 2026-06-19
- **Last confirmed live:** 2026-10-24
- **Apply:** https://job-boards.greenhouse.io/remixtherapeutics/jobs/4707921005

## Job description

Remix Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that modulate RNA processing to address the underlying drivers of disease. Our lead clinical program, REM-422, targets the RNA splicing machinery and is currently being evaluated in adenoid cystic carcinoma (ACC), a rare salivary gland cancer, as well as acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS).

Position Summary:

Remix is seeking a Vice President, Clinical Development to provide medical and clinical leadership for REM-422 and contribute to the development of future programs across the portfolio.

Reporting directly to the Chief Medical Officer and based at our Watertown, MA headquarters, this individual will play a central role in clinical strategy, trial execution, medical monitoring, and interpretation of emerging clinical and translational data. The role offers significant visibility to senior leadership and the opportunity to influence key development decisions at an important point in the company's growth.

This is a highly hands-on leadership position within a small, experienced, and collaborative organization. They will work closely with Clinical Operations, Regulatory Affairs, Biostatistics, Pharmacovigilance, Translational Medicine, external investigators, and key opinion leaders to drive the clinical development of REM-422.

Key Responsibilities:

Clinical Development Strategy & Leadership

- Provide medical and scientific leadership for REM-422 clinical development, contributing to overall program strategy, indication prioritization, clinical development plans, and key development decisions.
- Translate evolving clinical and translational findings into clear recommendations for the CMO, senior leadership, and cross-functional program teams.
- Contribute to protocol strategy and trial design, including patient population, dose and schedule, endpoints, biomarker strategy, and benefit-risk considerations.
- Provide clinical and scientific input to broader portfolio and pipeline discussions as appropriate.
- Author and review clinical development documents, including protocols and protocol amendments, investigator brochures, informed consent forms, clinical study reports, safety narratives, and other key clinical documents.

Clinical Trial Execution & Medical Monitoring

- Provide ongoing medical oversight of clinical trials, including review of safety data, laboratory findings, adverse events, dose modifications, protocol deviations, and emerging clinical trends.
- Participate in ongoing safety reviews, dose-escalation and cohort-review meetings, and other clinical governance activities.
- Partner with Clinical Operations to support site selection, site engagement, patient recruitment, enrollment strategy, and overall study execution.

Clinical Data Interpretation & Communication

- Lead or contribute to integrated review of clinical data, including safety, efficacy, PK/PD, pharmacodynamic, and biomarker datasets.
- Work closely with Biostatistics, Data Management, Translational Medicine, and Clinical Operations to ensure timely and rigorous review of emerging data.
- Contribute to data presentations for investigators, advisory boards, scientific congresses, executive leadership, and other stakeholders.
- Support abstracts, posters, manuscripts, and other scientific communications related to clinical programs.

Qualifications:

Required

- MD or equivalent medical degree.
- Fellowship training in hematology/oncology, medical oncology, or a closely related oncology specialty.
- Approximately 5+ years of clinical development experience within the biotechnology or pharmaceutical industry; exceptional candidates with somewhat less experience but significant relevant responsibility may also be considered.
- Meaningful hands-on experience as a medical monitor or clinical study physician in oncology development.
- Demonstrated experience with the design, conduct, and interpretation of oncology clinical trials, particularly early-stage clinical development.
- Experience reviewing serious adverse events, clinical safety data, eligibility questions, protocol deviations, and other medical-monitoring activities.
- Strong understanding of oncology drug development, including dose escalation, dose optimization, response assessment, safety evaluation, and benefit-risk assessment.
- Working knowledge of ICH/GCP guidelines and FDA regulatory requirements.
- Strong scientific and clinical judgment, with the ability to engage deeply with translational science, pharmacology, biomarkers, and mechanism-of-action data.
- Ability to integrate complex and evolving clinical datasets and translate them into clear, actionable development recommendations.
- Excellent written and verbal communication skills, including experience authoring or reviewing protocols, regulatory documents, safety narratives, and other clinical-development materials.
- Demonstrated ability to operate effectively in a highly collaborative, cross-functional, and fast-paced biotechnology environment.

## Preferred

- Experience developing therapies for rare solid tumors, adenoid cystic carcinoma, or head and neck cancers.
- Experience in hematologic malignancies, particularly AML and/or MDS.
- Experience with molecularly defined, biomarker-driven, or genomically selected patient populations.
- Experience with first-in-human, dose-escalation, and proof-of-concept oncology studies.
- Exposure to later-stage development, registrational strategy, or regulatory interactions supporting advancement toward registration.

Salary Range:

$293,000 - $358,000 USD

This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable.  Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.

## About Remix Therapeutics

## Company Overview
- **One-liner**: Clinical-stage biotechnology company developing first-in-class oral small molecule therapies that reprogram RNA processing to address previously undruggable drivers of cancer and other diseases.
- **Entity Type**: Private (Venture-backed; merged with Passage Bio in June 2026 with a concurrent $100M private placement)
- **Headquarters**: Watertown, Massachusetts, United States
- **Founded**: 2018
- **Founders**: Peter Smith, PhD

## Core Business
- **Primary industry**: Biotechnology – RNA-targeted therapeutics, oncology
- **Target customers**: B2B (pharmaceutical partners like Roche and Johnson & Johnson) and B2C (patients with high-unmet-need cancers, served through healthcare providers)
- **Mission or purpose statement**: “Reprogramming RNA to transform patients’ lives” – focused on modulating RNA processing to address disease drivers at their origin

## Products & Services
- **REM‑422**: First-in-class, orally available small molecule mRNA degrader targeting the historically undruggable transcription factor MYB. Currently in Phase 1 clinical trials for acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR‑MDS), and adenoid cystic carcinoma (ACC). Granted FDA Fast Track designation for ACC.
- **REMaster™ Drug Discovery Platform**: Proprietary platform that designs small molecules to harness cellular RNA‑processing machinery, enabling modulation of gene expression for targets previously considered intractable. Used for internal pipeline and partnered programs.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed (private company; post-merger valuation unknown)
- **Key Metric**: Total funding ~$240.7M (including a $100M private placement concurrent with the Passage Bio merger in June 2026). Annual revenue (2025 estimate): $3.2M (typical for a clinical‑stage biotech).
- **Notable Investors/Partners**:  
  - Investors: Surveyor Capital (Series B lead, $70M), Foresite Capital (Series A lead, $65M), The Column Group (Venture Round lead, $60M)  
  - Partners: Roche (collaboration for RNA‑processing modulators), Johnson & Johnson Innovative Medicine (multi‑year, three‑target oncology/immunology collaboration)  
- **Growth Signals**:  
  - Preliminary Phase 1 data for REM‑422 showed strong anti‑tumor activity and favorable safety in ACC  
  - FDA Fast Track designation for REM‑422 in ACC  
  - Merger with Passage Bio (June 2026) brings additional capital and pipeline synergies  
  - Active job postings up 200% month‑over‑month and quarter‑over‑quarter  
  - Headcount of 49 employees with a heavy concentration in research (43%)

## Competitive Advantages
- **Proprietary REMaster platform** uniquely enables oral small‑molecule modulation of RNA processing, expanding the druggable target space beyond traditional protein inhibition
- **First‑in‑class oral MYB mRNA degrader** (REM‑422) addresses a transcription factor long considered undruggable
- **Top‑tier pharma collaborations** with Roche and J&J validate the technology and provide non‑dilutive funding
- **Strong scientific leadership** (CEO/co‑founder Peter Smith, PhD, formerly CSO at H3 Biomedicine, where he advanced three molecules to the clinic)

## Strategic Focus
- Advance REM‑422 through Phase 1 trials across multiple MYB‑driven cancers (AML, HR‑MDS, ACC) and expand into additional solid tumors
- Leverage the REMaster platform to discover new RNA‑processing modulators for oncology and immunology
- Deepen existing pharma partnerships and seek new collaborations to accelerate pipeline growth
- Integrate the recently merged Passage Bio assets and utilize the $100M private placement to fund clinical development

## Why Work Here
- **Culture**: Values-driven environment centered on “True to Our RNA” (scientific integrity), “Courageous Curiosity” (bold innovation), and “Remixing Together” (collaboration and mutual support). Employees describe a flat, science‑first culture where diverse perspectives are welcomed.
- **Work model**: Hybrid? While not explicitly stated, the company has three offices in the Boston area (Watertown HQ, One Kendall Square Cambridge, and another Cambridge location). Lab‑based roles are likely on‑site; corporate roles may offer flexibility.
- **Perks & environment**: Small company (~49 people) with the energy of a startup but backed by significant funding and pharma partnerships. Employees share a strong sense of mission to bring new therapies to patients with few options. “We take our work seriously but not ourselves.”
- **Growth opportunity**: Rapidly advancing clinical pipeline and post‑merger expansion offer career advancement in a high‑visibility biotech. Recent ramp‑up in hiring (3 active postings for senior leadership roles like VP of Program Team Lead, VP of Biostatistics, and Senior Manager of Strategy & BD) signals scaling.

## Sources
1. [Remix Therapeutics Home](https://www.remixtx.com/)
2. [Remix Therapeutics About Us](https://www.remixtx.com/about/)
3. [Remix Therapeutics Join Us](https://www.remixtx.com/join/)
4. [Remix Therapeutics LinkedIn](https://www.linkedin.com/company/remix-therapeutics)
5. [Remix Therapeutics Greenhouse Careers](https://job-boards.greenhouse.io/remixtherapeutics)

## Other roles at Remix Therapeutics

- [Senior Director, GCP Quality](https://feeny.ai/job/senior-director-gcp-quality-remix-therapeutics-watertown-ancn66bxrnf3) — Watertown, MA
- [Associate Director, Clinical Data Management](https://feeny.ai/job/associate-director-clinical-data-management-remix-therapeutics-watertown-qq070g410ywh) — Watertown, MA
- [Head of Medical Affairs](https://feeny.ai/job/head-of-medical-affairs-remix-therapeutics-watertown-x0b0ddpp9nnc) — Watertown, MA
- [Vice President/Senior Director, Nonclinical Drug Safety & Toxicology](https://feeny.ai/job/vice-president-senior-director-nonclinical-drug-safety-toxicology-remix-hcv58wta0q0b) — Watertown, MA
- [Vice President, Clinical Development](https://feeny.ai/job/vice-president-clinical-development-tango-therapeutics-boston-w8pcvx8mc2zx) — Boston, MA
- [Vice President, Clinical Development](https://feeny.ai/job/vice-president-clinical-development-4d-molecular-therapeutics-united-states-8zdnvfs5n4ha) — United States
- [Vice President, Clinical Development](https://feeny.ai/job/vice-president-clinical-development-kardigan-princeton-yvmee393a5pb) — Princeton, NJ